XORTX Therapeutics Inc Dossier - Source-backed chat

XORTX Therapeutics Inc

XRTXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.63

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.69Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $3.1M

Enterprise Value −$15.7M

Shares Outstanding 1.8M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

XORTX Therapeutics is a late-stage clinical pharmaceutical company focusing on aberrant purine metabolism and xanthine oxidase inhibition to treat gout and progressive kidney diseases. The company has strategically pivoted to prioritize its lead gout program, XRx-026 (XORLO), targeting a $700 million annual market of patients intolerant to allopurinol. While the 505(b)(2) regulatory pathway provides a de-risked and accelerated timeline to a potential NDA filing within 18 months, XORTX faces severe going concern risks with a lean cash balance of $864,514 as of December 31, 2025, offset slightly by a subsequent $5 million public offering in May 2026. A 'Hold' recommendation is advised until clinical execution of the XRX-OXY-102 bridging study begins and further capital runway is secured.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The XRX-OXY-102 bridging study experiences clinical or regulatory delays, or fails to demonstrate therapeutic equivalence to allopurinol. Ongoing cash burn exhausts the proceeds from the May 2026 public offering, and the company is unable to secure further financing under favorable terms, leading to severe dilution or a halt in clinical development.

Base CaseCentral scenario

The company successfully files its IND and initiates the XRX-OXY-102 bridging study for XRx-026. Positive pharmacokinetic and therapeutic equivalence data versus allopurinol are generated, supporting an NDA submission under the 505(b)(2) pathway within 18 months. The company leverages its newly acquired VB4-P5 renal anti-fibrotic program and advances XRx-008 for ADPKD toward a registration-enabling study, while securing additional dilutive or non-dilutive funding to sustain operations.

Bull CaseUpside scenario

XORTX's lead drug candidate XORLO™ (XRx-026) for gout is clinically de-risked and targets a large, well-established $700 million market of allopurinol-intolerant patients with an NDA filing planned within the next 12-18 months. Additionally, its XRx-008 program for ADPKD targets a >$5 billion market with orphan drug designation and potential accelerated approval pathways.

Scenarios reflect our research view at the research date.

Key Investment Merits

De-risked regulatory path using the FDA's 505(b)(2) pathway for XORLO, relying on existing clinical safety data of oxypurinol.
Targeting a high-value niche of allopurinol-intolerant gout patients, representing an estimated $700 million annual market opportunity in the US.
Expanded cardiorenal pipeline with the acquisition of Vectus Biosystems' VB4-P5 renal anti-fibrotic program, adding broad IP across 30+ jurisdictions.
Strengthened leadership team with the appointment of Mika Grasso as co-CEO to optimize public markets efficiency and financial strategy.

Key Investment Risks

Significant going concern uncertainty, requiring continuous capital raises to fund expensive clinical trials.
Clinical development risk associated with the upcoming XRX-OXY-102 bridging study.
Regulatory hurdles if the FDA requests additional clinical data beyond the proposed bridging study.
Delisting and liquidity risks, though mitigated by the voluntary delisting from the TSX Venture Exchange to focus solely on the Nasdaq listing.

Thesis Invalidation Triggers

Failure of the XRX-OXY-102 study to demonstrate pharmacokinetic equivalence or therapeutic equivalence.
Inability to raise additional capital, leading to a suspension of the XRx-026 or XRx-008 clinical programs.
FDA rejection of the 505(b)(2) pathway eligibility for XORLO.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.